enVVeno Medical Email Formats

Medical Equipment Manufacturing • Irvine, California, United States • 21-50 Employees

enVVeno Medical Email Formats

enVVeno Medical uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@envveno.com), used 62.5% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@envveno.com	62.5%
{first name}{last name}	johndoe@envveno.com	28.1%
{last name}{last name}	doedoe@envveno.com	9.4%

Key Contacts at enVVeno Medical

Hamed Alavi

Chief Technology Officer, Senior Vice President

Robert Berman

Chief Executive Officer And Member, Board Of Directors

Nilesh Kanse

Associate Director, Clinical Data Management

Nicholas Williams

Director Of Manufacturing

Taj Muhammad

Director Of Clinical Integration & Strategy

Company overview

Headquarters	70 Doppler, Irvine, CA 92618, US
Phone number	+19492612900
Website	envveno.com
NAICS	3391
SIC	801
Keywords	Vascular And Venous Disease
Employees	21-50
Socials

About enVVeno Medical

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care in the treatment of venous disease. The Company’s lead product, the VenoValve®, is a first-in-class implant being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). In healthy patients, valves inside the veins of the leg assist in propelling blood up the leg, and back to the heart and lungs. Affecting approximately 2.4 million people in the United States, CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Implanted into the femoral vein, the VenoValve is designed to act as a one-way valve, to help restore proper blood flow in the leg. The VenoValve is currently being evaluated in the SAVVE pivotal study.